WO2011034832A1 - Substituted phenoxymethyl dihydro oxazolopyrimidinones, preparation and use thereof - Google Patents

Substituted phenoxymethyl dihydro oxazolopyrimidinones, preparation and use thereof Download PDF

Info

Publication number
WO2011034832A1
WO2011034832A1 PCT/US2010/048697 US2010048697W WO2011034832A1 WO 2011034832 A1 WO2011034832 A1 WO 2011034832A1 US 2010048697 W US2010048697 W US 2010048697W WO 2011034832 A1 WO2011034832 A1 WO 2011034832A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
oxazolo
phenoxymethyl
pyrimidin
cyclohexyl
Prior art date
Application number
PCT/US2010/048697
Other languages
English (en)
French (fr)
Inventor
Raymond Walter Kosley, Jr.
Rosy Sher
Kent W. Neuenschwander
Vieroslava Gurunian
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of WO2011034832A1 publication Critical patent/WO2011034832A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2010/048697 2009-09-15 2010-09-14 Substituted phenoxymethyl dihydro oxazolopyrimidinones, preparation and use thereof WO2011034832A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24258909P 2009-09-15 2009-09-15
US61/242,589 2009-09-15
FR1055808 2010-07-16
FR1055808 2010-07-16

Publications (1)

Publication Number Publication Date
WO2011034832A1 true WO2011034832A1 (en) 2011-03-24

Family

ID=43014314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/048697 WO2011034832A1 (en) 2009-09-15 2010-09-14 Substituted phenoxymethyl dihydro oxazolopyrimidinones, preparation and use thereof

Country Status (3)

Country Link
AR (1) AR078172A1 (es)
TW (1) TW201124421A (es)
WO (1) WO2011034832A1 (es)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504622A (ja) * 2009-09-15 2013-02-07 サノフイ 置換ジヒドロベンゾシクロアルキルオキシメチルオキサゾロピリミジノン、その製造及び使用
WO2013062079A1 (ja) * 2011-10-28 2013-05-02 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9067891B2 (en) 2007-03-07 2015-06-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
KR20160104579A (ko) * 2015-02-26 2016-09-05 에스케이바이오팜 주식회사 이미다조피리미딘 및 이미다조트리아진 유도체, 및 이를 포함하는 약제학적 조성물
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
WO2018129609A1 (en) * 2017-01-10 2018-07-19 Owen-Barry Pharmaceuticals Inc. Anticonvulsant compounds
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112483A2 (en) 2007-03-09 2008-09-18 Sanofi-Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112483A2 (en) 2007-03-09 2008-09-18 Sanofi-Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.", 1995, AMERICAN PSYCHIATRIC ASSOCIATION
ALEXANDER ET AL., EPILEPSY RES., vol. 71, no. 1, 2006, pages 1 - 22
BORSINI ET AL., PSYCHOPHARMACOLOGY, vol. 98, no. 2, 1989, pages 207 - 11
CHAVEZ-NORIEGA, CURRENT DRUG TARGETS - CNS & NEUROLOGICAL DISORDERS, vol. L, 2002, pages 261 - 281
FEINBERG ET AL., PHARMACOL BIOCHEM BEHAV., vol. 73, no. 2, 2002, pages 467 - 74
FORFAR I ET AL: "An easy Rout to 2-Substituted-2,3-dihydro-5(7)H-oxazolo(3,2-a)pyrimid in-5-ones and 7-ones Starting from the Corresponding 2-Amino-2-oxazolines", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC, US LNKD- DOI:10.1002/JHET.5570380403, vol. 38, no. 4, 1 July 2001 (2001-07-01), pages 823 - 827, XP002504930, ISSN: 0022-152X *
FORFAR I ET AL: "Synthesis, Structure, and Preliminary Evaluation of Cycloaddition Compounds with Unsaturated Carboxylic Esters", ARCHIV DER PHARMAZIE, WILEY - VCH VERLAG GMBH & CO. KGAA, DE LNKD- DOI:10.1002/ARDP.19903231105, vol. 323, no. 11, 1 January 1990 (1990-01-01), pages 905 - 909, XP002504929, ISSN: 0365-6233 *
GALICI ET AL., J PHARMACOL EXP THER., vol. 318, no. 1, July 2006 (2006-07-01), pages 173 - 85
GEWIRTZ ET AL., PHARMACOL BIOCHEM BEHAV., vol. 73, no. 2, September 2002 (2002-09-01), pages 317 - 26
HELTON ET AL., J PHARMACOL EXP THER., vol. 284, no. 2, February 1998 (1998-02-01), pages 651 - 660
J ORG CHEM, vol. 46, 1981, pages 1532
J ORG CHEM, vol. 55, no. 8, 1990, pages 2374 - 237
J ORG CHEM., vol. 46, 1981, pages 1532
J. CHEM. SOC., PERKIN TRANS. 1, 1989, pages 1705 - 1706
J. ORG. CHEM., vol. 46, 1981, pages 3784 - 3789
JOHNSON ET AL., PSYCHOPHARMACOLOGY (BERL), vol. 179, no. 1, April 2005 (2005-04-01), pages 271 - 83
JONES ET AL., NEUROPHARMACOLOGY, vol. 49, no. 1, 2005, pages 206 - 18
KAWASHIMA ET AL., NEUROSCI. LETT., vol. 378, no. 3, 2005, pages 131 - 4
KELLNER ET AL., PSYCHOPHARMACOLOGY (BERL), vol. 179, no. 1, April 2005 (2005-04-01), pages 310 - 5
KLODZINSKA ET AL., POL J PHARMACOL., vol. 51, no. 6, 1999, pages 543 - 5
KRYSTAL ET AL., PSYCHOPHARMACOLOGY (BERL), vol. 179, no. 1, April 2005 (2005-04-01), pages 303 - 9
LEE ET AL., BRAIN RESEARCH, vol. 1249, 2009, pages 244 - 250
MOGHADDAM, PSYCHOPHARMACOLOGY, vol. 174, 2004, pages 39 - 44
MONAGHAN; BRIDGES; COLTMAN, ANNUAL REVIEWS IN PHARMACOLOGY AND TOXICOLOGY, vol. 29, 1989, pages 365
OLIVIER ET AL., EUR J PHARMACOL., vol. 463, 2003, pages 117 - 32
PATIL ET AL., NATURE MEDICINE, vol. 13, no. 9, September 2007 (2007-09-01), pages 1102 - 7
RORICK-KEHN ET AL., J. PHARMACOL. EXP. THER., vol. 316, no. 2, February 2006 (2006-02-01), pages 905 - 13
SABBATINI; MICHELI, EXPERT OPIN. THER. PATENTS, vol. 14, no. 11, 2004, pages 1593 - 1604
SAMADI ET AL., NEUROPHARMACOLOGY, vol. 54, 2008, pages 258 - 268
SCHECHTER ET AL., NEURORX., vol. 2, no. 4, October 2005 (2005-10-01), pages 590 - 611
TATARCZYNSKA ET AL., PSYCHOPHARMACOLOGY (BERL)., vol. 158, no. L, October 2001 (2001-10-01), pages 94 - 9
TETRAHEDRON LETTERS, vol. 48, no. 3, 2007, pages 377 - 380
TETRAHEDRON, 2006, pages 5697 - 5708
THOMSEN ET AL., J NEUROCHEM., vol. 62, no. 6, 1994, pages 2492 - 5
THOMSEN ET AL., NEUROPHARMACOLOGY, vol. 37, no. 12, 1998, pages 1465 - 73
WATKINS; EVANS, ANNUAL REVIEWS IN PHARMACOLOGY AND TOXICOLOGY, vol. 21, 1981, pages 165
WATKINS; KROGSGAARD-LARSEN; HONORE, TRANSACTIONS IN PHARMACEUTICAL SCIENCE, vol. 11, 1990, pages 25

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US9067891B2 (en) 2007-03-07 2015-06-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US11071729B2 (en) 2007-09-14 2021-07-27 Addex Pharmaceuticals S.A. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US10071095B2 (en) 2009-05-12 2018-09-11 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
US9737533B2 (en) 2009-05-12 2017-08-22 Janssen Pharmaceuticals. Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
JP2013504622A (ja) * 2009-09-15 2013-02-07 サノフイ 置換ジヒドロベンゾシクロアルキルオキシメチルオキサゾロピリミジノン、その製造及び使用
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2013062079A1 (ja) * 2011-10-28 2013-05-02 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US11103506B2 (en) 2014-01-21 2021-08-31 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR102577178B1 (ko) 2015-02-26 2023-09-11 에스케이바이오팜 주식회사 이미다조피리미딘 및 이미다조트리아진 유도체, 및 이를 포함하는 약제학적 조성물
KR20160104579A (ko) * 2015-02-26 2016-09-05 에스케이바이오팜 주식회사 이미다조피리미딘 및 이미다조트리아진 유도체, 및 이를 포함하는 약제학적 조성물
WO2018129609A1 (en) * 2017-01-10 2018-07-19 Owen-Barry Pharmaceuticals Inc. Anticonvulsant compounds
US11345652B2 (en) 2017-01-10 2022-05-31 Owen-Barry Pharmaceuticals Anticonvulsant compounds
EP3568388A4 (en) * 2017-01-10 2020-10-14 Owen-Barry Pharmaceuticals Inc. ANTICONVULSIVE CONNECTIONS
US10556853B2 (en) 2017-01-10 2020-02-11 Owen-Barry Pharmaceuticals Inc. Anticonvulsant compounds

Also Published As

Publication number Publication date
TW201124421A (en) 2011-07-16
AR078172A1 (es) 2011-10-19

Similar Documents

Publication Publication Date Title
WO2011034832A1 (en) Substituted phenoxymethyl dihydro oxazolopyrimidinones, preparation and use thereof
JP5351056B2 (ja) 置換されたジヒドロ及びテトラヒドロオキサゾロピリミジノン、その製造並びに使用
CA2773555C (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
EP2268645B1 (en) Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
RU2603140C2 (ru) Соединения имидазотриазинона
EP3675848B1 (en) Spirocycle compounds and methods of making and using same
WO2011034828A1 (en) Substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones, preparation and use thereof
IL157470A (en) History of isoxazoline used as antidepressants
WO2023097230A1 (en) Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
US8207181B2 (en) Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10757347

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10757347

Country of ref document: EP

Kind code of ref document: A1